Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Repisalud
Publicación Artículo científico (JournalArticle)

Influence of Subclinical Atherosclerosis Burden and Progression on Mortality.

  • Fuster, Valentin
  • García-Álvarez, Ana
  • Devesa, Ana
  • Mass, Virginia
  • Owen, Ruth
  • Quesada, Antonio
  • Fuster, José J
  • García-Lunar, Inés
  • Pocock, Stuart
  • Sánchez-González, Javier
  • Sartori, Samantha
  • Peyra, Carlos
  • Andres, Vicente
  • Muntendam, Pieter
  • Ibanez, Borja
Atherosclerosis is a dynamic process. There is little evidence regarding whether quantification of atherosclerosis extent and progression, particularly in the carotid artery, in asymptomatic individuals predicts all-cause mortality. This study sought to evaluate the independent predictive value (beyond cardiovascular risk factors) of subclinical atherosclerosis burden and progression and all-cause mortality. A population of 5,716 asymptomatic U.S. adults (mean age 68.9 years, 56.7% female) enrolled between 2008 and 2009 in the BioImage (A Clinical Study of Burden of Atherosclerotic Disease in an At Risk Population) study underwent examination by vascular ultrasound to quantify carotid plaque burden (cPB) (the sum of right and left carotid plaque areas) and by computed tomography for coronary artery calcium (CAC). Follow-up carotid vascular ultrasound was performed on 732 participants a median of 8.9 years after the baseline exam. All participants were followed up for all-cause mortality, the primary outcome. Trend HRs are the per-tertile increase in each variable. Over a median 12.4 years' follow-up, 901 (16%) participants died. After adjustment for cardiovascular risk factors and background medication, baseline cPB and CAC score were both significantly associated with all-cause mortality (fully adjusted trend HR: 1.23; 95% CI: 1.16-1.32; and HR: 1.15; 95% CI: 1.08-1.23), respectively (both P < 0.001), thus providing additional prognostic value. cPB performed better than CAC score. In participants with a second vascular ultrasound evaluation, median cPB progressed from 29.2 to 91.3 mm. cPB progression was significantly associated with all-cause mortality after adjusting for cardiovascular risk factors and baseline cPB (HR: 1.03; 95% CI: 1.01-1.04 per absolute 10-mm change; P = 0.01). Subclinical atherosclerosis burden (cPB and CAC) in asymptomatic individuals was independently associated with all-cause mortality. Moreover, atherosclerosis progression was independently associated with all-cause mortality.
Repisalud
Publicación Artículo científico (JournalArticle)

Remote ischemic conditioning protects against anthracycline cardiotoxicity without impairing its antitumor activity.

  • Díaz-Guerra, Anabel
  • Clemente-Moragón, Agustín
  • Pollán, Ángela
  • López-Palomar, Lucía
  • Cádiz, Laura
  • Ibáñez, Borja
Anthracyclines remain a cornerstone of treatment for many cancer types; however, their cardiotoxic potential leads to cardiac dysfunction in a substantial proportion of patients, ultimately compromising long-term quality of life. Few strategies have proven effective in preventing anthracycline-induced cardiotoxicity (AIC). Among them, remote ischemic conditioning (RIC) has emerged as one of the most promising, having shown robust cardioprotective potential in preclinical studies and currently being evaluated in clinical trials. However, it remains unclear whether this intervention, while protecting the heart, could also inadvertently protect tumors from the cytotoxic effects of anthracyclines, thereby reducing their antitumor efficacy. In this study, we investigated whether RIC protects against AIC in a tumor-bearing mouse model, allowing simultaneous assessment of both cardiac and tumoral responses. Cutaneous tumors were induced in CD1 mice using a DMBA/TPA protocol, followed by five weekly intraperitoneal injections of doxorubicin (5 mg/kg). Mice bearing tumors were randomized to receive doxorubicin alone or in combination with weekly RIC (three cycles of 5 min hindlimb ischemia/reperfusion). Longitudinal echocardiography was used to assess cardiac function, while tumor growth, survival, and body weight were monitored throughout the protocol. Doxorubicin treatment reduced overall survival, inhibited tumor growth, and induced left ventricular systolic dysfunction and cardiac atrophy compared with untreated controls. RIC preserved left ventricular ejection fraction, partially attenuated early left ventricular atrophy, and showed a trend towards improved survival, without attenuating the antitumor efficacy of doxorubicin, as tumor suppression remained comparable between treatment groups. These findings demonstrate that RIC preserves cardiac systolic function during anthracycline chemotherapy in tumor-bearing mice without impairing the antitumor efficacy of the drug. The results support RIC as a simple, safe, and low-cost non-pharmacological strategy to mitigate AIC with potential translational relevance for oncology patients.
Repisalud
Publicación Artículo científico (JournalArticle)

Update on preclinical models of cancer therapy-related cardiac dysfunction: Challenges and perspectives. A scientific statement of the Heart Failure Association (HFA) of the ESC, the ESC Council of Cardio-Oncology, and the ESC Working Group on Cellular Biology of the Heart.

  • Ghigo, Alessandra
  • Ameri, Pietro
  • Asnani, Aarti
  • Bertero, Edoardo
  • de Boer, Rudolf A
  • Farmakis, Dimitrios
  • González, Arantxa
  • Heymans, Stephane
  • Ibáñez, Borja
  • López-Fernández, Teresa
  • Lyon, Alexander R
  • Pollesello, Piero
  • Rakisheva, Amina
  • Stellos, Konstantinos
  • Streckfuss-Bömeke, Katrin
  • Tocchetti, Carlo Gabriele
  • Thum, Thomas
  • van der Meer, Peter
  • Van Rooij, Eva
  • Ponikowski, Piotr
  • Metra, Marco
  • Rosano, Giuseppe
  • Van Linthout, Sophie
New anticancer therapies with potential cardiovascular side effects are continuously being introduced into clinical practice, with new and often unexpected toxicities becoming apparent only after clinical introduction. These unknown toxicities should be identified and understood beforehand to better prepare patients and physicians, enabling the implementation of effective treatments. Therefore, there is a crucial need for appropriate preclinical models to understand the biological basis of their cardiotoxicity. This scientific statement summarizes the preclinical models hitherto used, from in vitro two- and three-dimensional human systems to small and large animals, to pinpoint the molecular mechanisms behind the cardiotoxicity of new-generation anticancer therapies, particularly immunotherapies, and to develop potential cardioprotective strategies. Furthermore, it discusses how preclinical models have contributed to the provocative concept of heart failure being potentially tumorigenic and how the discovery of drugs with both anticancer and cardioprotective actions has revealed a common mechanistic basis for heart failure and cancer. Finally, it discusses the existing gaps between preclinical models and clinical observations in patients, how these discrepancies affect regulatory pathways and the drug development process in cardio-oncology and provides recommendations for closing these gaps.
Repisalud
Publicación Artículo científico (JournalArticle)

The impact of type 2 immunity and allergic diseases in atherosclerosis.

  • Fernández-Gallego, Nieves
  • Castillo-González, Raquel
  • Méndez-Barbero, Nerea
  • López-Sanz, Celia
  • Obeso, David
  • Villaseñor, Alma
  • Escribese, María M
  • López-Melgar, Beatriz
  • Salamanca, Jorge
  • Benedicto-Buendía, Amparo
  • Jiménez-Borreguero, Luis Jesús
  • Ibáñez, Borja
  • Sastre, Joaquín
  • Belver, María Teresa
  • Vega, Francisco
  • Blanco, Carlos
  • Barber, Domingo
  • Sánchez-Madrid, Francisco
  • de la Fuente, Hortensia
  • Martin, Pilar
  • Esteban, Vanesa
  • Jiménez-Saiz, Rodrigo
  • Fernández‐Gallego, Nieves
  • Castillo‐González, Raquel
  • Méndez‐Barbero, Nerea
  • López‐Sanz, Celia
  • Escribese, María M.
  • López‐Melgar, Beatriz
  • Benedicto‐Buendía, Amparo
  • Jiménez‐Borreguero, Luis Jesús
  • Sánchez‐Madrid, Francisco
  • Jiménez‐Saiz, Rodrigo
Allergic diseases are allergen-induced immunological disorders characterized by the development of type 2 immunity and IgE responses. The prevalence of allergic diseases has been on the rise alike cardiovascular disease (CVD), which affects arteries of different organs such as the heart, the kidney and the brain. The underlying cause of CVD is often atherosclerosis, a disease distinguished by endothelial dysfunction, fibrofatty material accumulation in the intima of the artery wall, smooth muscle cell proliferation, and Th1 inflammation. The opposed T-cell identity of allergy and atherosclerosis implies an atheroprotective role for Th2 cells by counteracting Th1 responses. Yet, the clinical association between allergic disease and CVD argues against it. Within, we review different phases of allergic pathology, basic immunological mechanisms of atherosclerosis and the clinical association between allergic diseases (particularly asthma, atopic dermatitis, allergic rhinitis and food allergy) and CVD. Then, we discuss putative atherogenic mechanisms of type 2 immunity and allergic inflammation including acute allergic reactions (IgE, IgG1, mast cells, macrophages and allergic mediators such as vasoactive components, growth factors and those derived from the complement, contact and coagulation systems) and late phase inflammation (Th2 cells, eosinophils, type 2 innate-like lymphoid cells, alarmins, IL-4, IL-5, IL-9, IL-13 and IL-17).
Repisalud
Publicación Artículo científico (JournalArticle)

Four-Dimensional Magnetic Resonance Pulmonary Flow Imaging for Assessing Pulmonary Vasculopathy in Patients with Postcapillary Pulmonary Hypertension.

  • Nuche, Jorge
  • Ponz, Inés
  • Sánchez Sánchez, Violeta
  • Bóbeda, Javier
  • Gaitán, Ángel
  • López-Linares, Karen
  • García-Cosío, María Dolores
  • Sarnago Cebada, Fernando
  • González, Javier Sánchez
  • Arribas Ynsaurriaga, Fernando
  • Ruíz-Cabello, Jesús
  • Ibáñez, Borja
  • Delgado, Juan F
Noninvasive techniques for diagnosing combined postcapillary pulmonary hypertension (CpcPH) are unavailable. : To assess the diagnostic performance of cardiac magnetic resonance (CMR)-based four-dimensional (4D)-flow analysis in identifying CpcPH. : Prospective observational study of heart failure (HF) patients with suspected pulmonary hypertension (PH) who underwent simultaneous CMR and right heart catheterization. The 4D-flow biomarkers were calculated using an automatic pipeline. A predictive model including 4D-flow biomarkers associated with CpcPH with a -value < 0.20 was built to determine the diagnostic performance of 4D-flow analysis to identify CpcPH. : A total of 46 HF patients (55.4 ± 14 years, 63% male) with confirmed PH (19 [41%] isolated postcapillary PH [IpcPH], 27 [59%] CpcPH) were included. No differences were found in baseline characteristics, echocardiography, or CMR anatomical and functional parameters, except for a higher Doppler-estimated systolic pulmonary pressure and larger pulmonary artery in CpcPH patients. The 4D-flow CMR analysis was performed in 31 patients (67%). The maximal peak velocity (67.1 [62.2-77.5] cm/s-IpcPH vs. 58.2 [45.8-66.0] cm/s-CpcPH; = 0.021) and maximal helicity (339.9 [290.0-391.8]) cm/s-IpcPH vs. 226.0 (173.5-343.7) cm/s-CpcPH; = 0.026) were significantly lower in patients with CpcPH. A maximal multivariable model including sex, maximal average, and peak velocities, Reynolds number, flow rate, and helicity showed fair diagnostic performance (area under the curve: 0.768 [95%-CI: 0.572-0.963]; sensitivity: 100%; specificity: 55%). : In HF patients with PH, 4D-flow-derived maximal peak velocity and maximal helicity were significantly lower in CpcPH patients. A multiparametric model including maximal 4D-flow-derived biomarkers showed good diagnostic performance for identifying CpcPH.